Clinical Trial of TQB2825 in Subjects With CD20 Positive Hematological Tumors
Status:
Recruiting
Trial end date:
2023-12-01
Target enrollment:
Participant gender:
Summary
This is a single-group, open, dose escalation and expansion Phase I clinical study, with
phase I being a dose escalation study and Phase II being a dose expansion study. The purpose
of this study was to evaluate the safety and tolerability of TQB2825 injection in
CD20-positive hematological tumor subjects, and to determine dose-limiting toxicity (DLT),
maximum tolerated dose (MTD) (if any), or optimal biological dose (OBD), and recommended
phase II dose (RP2D).
Phase:
Phase 1
Details
Lead Sponsor:
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.